In October 2014, within the XXIV National Congress on Respiratory Diseases, Valenta received «For Contribution to the Development of Respiratory Medicine» award. Ingavirin was mentioned as effective and safe medicine for flu and ARVI.
In October 2014, at «Flu: the Urgency of Problem in Post-Pandemic Period» symposium held within the XXIV National Congress on Respiratory Diseases, Valenta was awarded «For Contribution to the Development of Respiratory Medicine». Within the event, A.G.Chuchalin, Academician of RAMS, Director of FSE Pulmonology Research Institute at FMBA of Russia, Chief Therapist of the Russian Federation, shared experience of Ingavirin application and made special mention of the company’s activity in combating viral diseases.
Ingavirin is one of most high-potential products in Valenta’s portfolios for immunology and virology. The medicine is intended for flu and ARVI and features antiviral action suppressing virus proliferation and dissemination in the patient’s organism. Besides, the medicine produces anti-inflammatory effect and suppresses production of key substances causing inflammation of tissues affected by viruses. According to Synovate Comcon, currently Ingavirin is the most prescribed medicine in general practice.
Ingavirin passed a full complex of necessary laboratory and clinical trials. The study of Ingavirin application by adult patients for flu and ARVI confirmed its effectiveness in reducing the period of fever, removing symptoms of intoxication (headache, weakness and dizziness) and inflammation of respiratory tract, decreasing occurrence of complications and reducing the total period of disease.
Special attention should be given to the results of the randomized multicenter trial of Ingavirin clinical effectiveness in treating children of the age of 13-17 for flu and ARVI. The study confirmed the high safety of the medicine, high levels of tolerability and effectiveness of its application. The results made possible the expansion of the range of antiviral medicines applied to treat children of the monitored age group.
Askar Bikkenin, Executive Director, OAO «Valenta Pharm»: «Immunology and virology are key therapeutic priorities for Valenta. We actively invest in the development of effective and safe innovations to fight flu and ARVI. In particular, clinical trials of Ingavirin aimed at expansion of the range of indications to its application have completely confirmed its efficacy and safety.»